Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone

KPV

A tripeptide fragment of α-MSH with no FDA-approved drug product. FDA reviewed KPV-related bulk substances for the 503A Bulks List at the 23 July 2026 PCAC meeting (wound healing and inflammatory conditions as the nominated uses).

Also listed as: Lys-Pro-Val, α-MSH (11-13)

Chemical identity

Compound class
Tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone
Sequence
KPV
Molecular formula
C16H30N4O4
Molecular weight
342.43 g/mol
CAS number
65189-71-1
PubChem CID
Unknown
Research categories
Peptide fragments, Preclinical research compounds

United States regulatory status

No FDA-approved product

  • No approved drug product exists in Drugs@FDA.
  • Listed on FDA's table of bulk substances nominated for compounding and subsequently withdrawn. FDA states it has not identified human exposure data.
  • On 23 July 2026 PCAC discussed KPV (free base) and KPV acetate (uses evaluated: wound healing and inflammatory conditions). FDA briefing materials proposed that they NOT be included on the 503A Bulks List. Nominations had been withdrawn; FDA elected to proceed. Committee recommendations are non-binding; FDA has not published a listing decision as of this review.

Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.

Evidence overview

4 records in this file

  • ANIMAL2
  • REGULATORY2

Research areas. Intestinal inflammation models; United States compounding.

Publication span. 2008–2026.

Open the evidence file

What we know

  • Two 2008 murine colitis papers (Dalmasso; Kannengiesser) are primary sources for the preclinical gut-inflammation literature.
  • No FDA-approved product exists. FDA's withdrawn-nominations table states that human exposure data have not been identified.
  • PCAC discussed KPV-related bulk substances on 23 July 2026. FDA briefing materials proposed against 503A Bulks List inclusion. That is not a listing decision.

Editorial reading of the records below, labelled as Therapept analysis. How records are built

What remains uncertain

  • Controlled human interventional data.
  • Whether commercial certificates labelled KPV describe Lys-Pro-Val rather than a related melanocortin fragment.

Sources

  1. FDA — Pharmacy Compounding Advisory Committee, 23–24 July 2026
  2. FDA — Certain bulk drug substances for use in compounding may present significant safety risks

Last reviewed 12 September 2026 · Compiled by Therapept Editorial · How these records are built